BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 17852143)

  • 21. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL; Qvigstad E; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2006 Oct; 55(3):278-87. PubMed ID: 16713143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits.
    Pedersen NG; Pedersen SH; Dalsgaard T; Lund CO; Nilas L; Ottesen B
    Maturitas; 2004 Dec; 49(4):304-14. PubMed ID: 15531126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions.
    Guvenal T; Durna A; Erden O; Guvenal F; Cetin M; Cetin A
    Adv Ther; 2009 Aug; 26(8):805-11. PubMed ID: 19672567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progestins and estrogens and Alzheimer's disease.
    Honjo H; Iwasa K; Kawata M; Fushiki S; Hosoda T; Tatsumi H; Oida N; Mihara M; Hirasugi Y; Yamamoto H; Kikuchi N; Kitawaki J
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):305-8. PubMed ID: 15860274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women.
    Ziaei S; Moaya M; Faghihzadeh S
    Climacteric; 2010 Jun; 13(3):249-53. PubMed ID: 19848555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density.
    Hofling M; Carlström K; Svane G; Azavedo E; Kloosterboer H; Von Schoultz B
    Gynecol Endocrinol; 2005 Feb; 20(2):110-5. PubMed ID: 15823831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.
    Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Kang WC; Han SH; Choi IS; Shin EK
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1889-94. PubMed ID: 12933531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.
    Valdivia I; Campodónico I; Tapia A; Capetillo M; Espinoza A; Lavín P
    Fertil Steril; 2004 Mar; 81(3):617-23. PubMed ID: 15037411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.